Mouli Chatterjee - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Mouli Chatterjee

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Molecular Omics|November 19, 2025

<i>STUB1</i> (CHIP) - a prognostic marker in cancerSubhajit Karmakar, Mouli Chatterjee, Malini Basu, et al.

European Journal of Pharmacology|February 14, 2025

CK2: The master regulator in tumor immune-microenvironment - A crucial target in oncotherapySubhajit Karmakar, Mouli Chatterjee, Malini Basu, et al.

Genes & Diseases|July 3, 2023

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patientsSunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Molecular Omics|November 19, 2025

<i>STUB1</i> (CHIP) - a prognostic marker in cancerSubhajit Karmakar, Mouli Chatterjee, Malini Basu, et al.

European Journal of Pharmacology|February 14, 2025

CK2: The master regulator in tumor immune-microenvironment - A crucial target in oncotherapySubhajit Karmakar, Mouli Chatterjee, Malini Basu, et al.

Genes & Diseases|July 3, 2023

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patientsSunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, et al.

Pageof 1